Bank of New York Mellon Corp Has $492.75 Million Holdings in Kenvue Inc. $KVUE

Bank of New York Mellon Corp trimmed its holdings in Kenvue Inc. (NYSE:KVUE) by 4.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 30,360,265 shares of the company’s stock after selling 1,254,065 shares during the quarter. Bank of New York Mellon Corp’s holdings in Kenvue were worth $492,747,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Norges Bank acquired a new position in Kenvue during the 2nd quarter valued at $537,418,000. Independent Franchise Partners LLP increased its holdings in shares of Kenvue by 233.4% during the 2nd quarter. Independent Franchise Partners LLP now owns 31,265,574 shares of the company’s stock worth $654,388,000 after purchasing an additional 21,886,537 shares during the period. American Century Companies Inc. raised its position in shares of Kenvue by 38.6% during the second quarter. American Century Companies Inc. now owns 30,265,020 shares of the company’s stock valued at $633,447,000 after buying an additional 8,436,166 shares during the last quarter. Amundi lifted its stake in shares of Kenvue by 82.5% in the second quarter. Amundi now owns 14,509,890 shares of the company’s stock valued at $305,446,000 after buying an additional 6,559,261 shares during the period. Finally, Vanguard Group Inc. grew its position in Kenvue by 1.8% during the second quarter. Vanguard Group Inc. now owns 233,246,267 shares of the company’s stock worth $4,881,844,000 after buying an additional 4,101,880 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling

In other Kenvue news, Director Jeffrey C. Smith purchased 3,200,000 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The stock was purchased at an average cost of $17.37 per share, with a total value of $55,584,000.00. Following the acquisition, the director directly owned 27,307,632 shares of the company’s stock, valued at approximately $474,333,567.84. This trade represents a 13.27% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 0.17% of the stock is currently owned by company insiders.

Kenvue Stock Down 0.8%

Shares of NYSE KVUE opened at $17.36 on Thursday. The stock has a market cap of $33.25 billion, a PE ratio of 23.14 and a beta of 0.60. The business has a fifty day moving average of $17.13 and a two-hundred day moving average of $18.08. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $25.17. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.98.

Kenvue (NYSE:KVUE) last announced its earnings results on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The business had revenue of $3.76 billion during the quarter, compared to analysts’ expectations of $3.83 billion. During the same quarter last year, the company posted $0.28 EPS. The firm’s revenue for the quarter was down 3.5% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, equities research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a dividend, which will be paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th will be issued a $0.2075 dividend. The ex-dividend date of this dividend is Wednesday, February 11th. Kenvue’s payout ratio is presently 110.67%.

Wall Street Analyst Weigh In

KVUE has been the subject of several recent research reports. Jefferies Financial Group cut their price target on Kenvue from $25.00 to $23.00 and set a “buy” rating for the company in a report on Monday, October 27th. Deutsche Bank Aktiengesellschaft set a $18.00 target price on Kenvue in a research note on Friday, October 24th. Citigroup reduced their target price on Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, October 9th. Edward Jones lowered shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. Finally, Canaccord Genuity Group restated a “hold” rating and issued a $15.00 price objective (down previously from $26.00) on shares of Kenvue in a research note on Wednesday, October 29th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $20.23.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.